Ruxolitinib(LuciRuX)

Release date: 2026-10-21 14:09:35     Recommended: 2

Indicated for the treatment of intermediate- or high-risk myelofibrosis in adults, polycythemia vera in patients with an inadequate response to hydroxyurea, and steroid-refractory acute or chronic